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Abstract
Background: Advances in high-throughput technologies and bioinformatics have transformed gene expression 
profiling methodologies. The results of microarray experiments are often validated using reverse transcription 
quantitative PCR (RT-qPCR), which is the most sensitive and reproducible method to quantify gene expression. 
Appropriate normalisation of RT-qPCR data using stably expressed reference genes is critical to ensure accurate and 
reliable results. Mi(cro)RNA expression profiles have been shown to be more accurate in disease classification than 
mRNA expression profiles. However, few reports detailed a robust identification and validation strategy for suitable 
reference genes for normalisation in miRNA RT-qPCR studies.
Methods: We adopt and report a systematic approach to identify the most stable reference genes for miRNA 
expression studies by RT-qPCR in colorectal cancer (CRC). High-throughput miRNA profiling was performed on ten 
pairs of CRC and normal tissues. By using the mean expression value of all expressed miRNAs, we identified the most 
stable candidate reference genes for subsequent validation. As such the stability of a panel of miRNAs was examined 
on 35 tumour and 39 normal tissues. The effects of normalisers on the relative quantity of established oncogenic (miR-
21 and miR-31) and tumour suppressor (miR-143 and miR-145) target miRNAs were assessed.
Results: In the array experiment, miR-26a, miR-345, miR-425 and miR-454 were identified as having expression profiles 
closest to the global mean. From a panel of six miRNAs (let-7a, miR-16, miR-26a, miR-345, miR-425 and miR-454) and two 
small nucleolar RNA genes (RNU48 and Z30), miR-16 and miR-345 were identified as the most stably expressed reference 
genes. The combined use of miR-16 and miR-345 to normalise expression data enabled detection of a significant 
dysregulation of all four target miRNAs between tumour and normal colorectal tissue.
Conclusions: Our study demonstrates that the top six most stably expressed miRNAs (let-7a, miR-16, miR-26a, miR-345, 
miR-425 and miR-454) described herein should be validated as suitable reference genes in both high-throughput and 
lower throughput RT-qPCR colorectal miRNA studies.
Background
Mi(cro)RNAs are short RNA molecules that bind (gener-
ally) to 3' UTR sequences of target messenger RNAs
(mRNAs), thereby modulating their expression patterns.
This modulated gene expression is manifest either as
translational repression [1], or mRNA degradation
whereby the RNA interference pathway is initiated to
remove targeted sequences [2]. MiRNAs play major roles
in governing diverse biological processes such as differ-
entiation, proliferation, and apoptosis [3,4]. Individual
miRNAs have been ascribed oncogenic and tumour sup-
pressor functions [5], and aberrant miRNA expression
has been implicated in many malignancies, including col-
orectal cancer (CRC) [6,7]. Previous study demonstrated
that miRNA profiles may be more accurate in disease
classification than mRNA profiles [8]. Moreover, miR-
NAs have been associated with CRC pathogenesis [9,10],
microsatellite stability status [11,12], therapeutic out-
come and prognosis [12-15].
High-throughput technology such as microarrays
enables simultaneous quantification of hundreds of miR-
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NAs in a single RNA sample. Meaningful interpretation
of such large datasets has been made possible by recent
advances in bioinformatics. It is critical that the findings
of microarray screening methodologies are validated to
produce scientifically robust results, using the most sen-
sitive and reproducible method of gene expression quan-
titation, reverse transcription quantitative PCR (RT-
qPCR) [16]. In order to achieve accurate, reproducible
and biologically relevant miRNA RT-qPCR data, non-
biological sample-to-sample variation that could be
introduced by protocol-dependent inconsistencies has to
be corrected for by using reference genes. Use of unreli-
able reference genes for normalisation may lead to inac-
curate quantitation of miRNAs of interest [17,18].
Previous studies have demonstrated that a single univer-
sal reference gene for all tissue types is unlikely to exist
[19-23], and the use of a single reference gene for normal-
isation leads to large errors and is therefore inappropriate
[22,24].
Despite increasing miRNA expression studies in CRC,
no previous report detailed a robust identification and
validation strategy for suitable reference genes for nor-
malization. The aim of this study was to identify the most
stable reference genes using a high-throughput approach,
in ten pairs of stage II colorectal tumour and normal tis-
sues. Following TaqMan array card analysis and the
established approach of finding miRNAs whose expres-
sion pattern is similar to the global mean expression [25],
miR-26a, miR-345, miR-425 and miR-454 were identified
as the most stably expressed miRNAs. The stability of
these miRNAs was further assessed by RT-qPCR in 74
colorectal tissues with an expanded panel of candidate
reference miRNAs (let-7a, miR-16) and two small nucleo-
lar RNAs (snoRNAs, RNU48 and Z30). Well established
oncogenic miRNAs in CRC: miR-21 [7,13,26] and miR-31
[7], and tumour suppressor miRNAs: miR-143 [6,27,28]
and miR-145 [6,7,12,27] were used as target miRNAs to
determine the effect of reference gene choice on relative
quantitation.
Methods
Colorectal tissue samples
Primary colorectal tissues consisting of 35 tumour speci-
mens and 39 normal tissues were obtained from 40
patients undergoing surgical resection or diagnostic
endoscopy at Galway University Hospital, Galway, Ire-
land. High-throughput miRNA profiling was performed
on ten pairs of corresponding tumour and normal tissues
from patients with stage II CRC [29], and these form part
of the subsequent validation cohort. Tissue samples were
immediately snap-frozen in liquid nitrogen following
retrieval and stored at -80°C. Written informed consent
was obtained from each patient and the study was
granted approval by the Clinical Research Ethics Com-
mittee of Galway University Hospital. Clinicopathological
data was collected prospectively and is summarised in
Table 1.
RNA extraction
To isolate small RNA (<200 nucleotides), approximately
100 mg of tissue was homogenised using a bench-top
homogeniser (Polytron PT1600E, Kinematica AG,
Lucerne, Switzerland) in 1-2 mL of Qiazol (Qiagen, UK).
Subsequent miRNA extraction was performed using the
RNeasy Mini Kit and the RNeasy MinElute Cleanup Kit
(Qiagen) according to the manufacturer's instructions.
Concentration and purity of miRNA was assessed using
the Nanodrop 1000 spectrophotometer (Nanodrop Tech-
nologies Inc., USA). Qualitative analysis of miRNA was
performed using the Agilent 2100 Bioanalyzer and the
Small RNA Assay (Agilent Technologies, USA) to deter-
mine the percentage of miRNA in the small RNA frac-
tion.
TaqMan array cards
A TaqMan Human MicroRNA array card is a high
throughput PCR-based miRNA array that enables analy-
sis of 384 miRNA assays on a microfluidic card. Each card
contains a mammalian U6 assay repeated 4 times, and an
assay unrelated to any mammalian species ath-miR-159a
to provide a process control. Simultaneous synthesis of
cDNA for mature miRNAs was performed using Mega-
plex Reverse Transcription Human Pool A (Applied Bio-
systems), which is a set of pre-defined pools of 380 stem-
looped reverse transcription primers. RT-qPCR was per-
formed using the Applied Biosystems 7900HT Fast Real-
Time PCR System, and default thermal-cycling condi-
tions.
Validation RT-qPCR
First strand cDNA was synthesised using gene-specific
stem-loop primers. The primer sequences of let-7a and
miR-16 have been previously described [30]. Primers
were obtained from MWG Biotech (Ebersberg, Germany)
if sequences were available. Otherwise, assays containing
stem-looped primer were purchased from Applied Bio-
systems. All reagents were included in the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems).
The reaction was performed using a GeneAmp PCR sys-
tem 9700 thermal cycler (Applied Biosystems) with sam-
ples incubated at 16°C for 30 minutes, 42°C for 30
minutes and 85°C for 5 minutes. An RT-negative control
was included in each batch of reactions.
The PCR reactions were carried out in final volumes of
20 μL using the Applied Biosystems 7900HT Fast Real-
Time PCR System. Reaction mix consisted of 10 μL 2 ×
TaqMan Fast Universal PCR Master Mix, No AmpErase
UNG, 1 μL 0.2 μM TaqMan probe, 3 μL 1.5 μM of for-
ward primer, 1.4 μL 0.7 μM reverse primer, and 1.33 μL of
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cDNA. The PCR reactions were initiated with 10 minutes
incubation at 95°C, followed by 40 cycles of 95°C for 15
seconds and 60°C for 60 seconds. Inter-assay control and
calibrator were included in each 96-well plate. All reac-
tions were performed in triplicate. The threshold stan-
dard deviation for intra- and inter-assay replicates was
0.3. PCR amplification efficiencies were calculated for
each candidate reference gene assay using the formula E =
(10-1/slope - 1) × 100, using the slope of the plot of quantifi-
cation cycle (Cq) versus log input of cDNA (10-fold dilu-
tion series). PCR amplification efficiencies for each
candidate reference gene are shown in Table 2.
Data analysis
High throughput data generated from TaqMan array card
RT-qPCR was analysed using qbasePLUS software (Bioga-
zelle, Belgium) [31]. Average values of triplicate Cq values
were converted to relative quantities for NormFinder and
geNorm analysis [21,32]. The relative expression of target
miRNAs (miR-21, miR-31, miR-143 and miR-145) norm-
alised to one or more reference candidates was also deter-
mined using qbasePLUS software employing a generalised
and universally applicable quantification model based on
efficiency correction, error propagation and multiple ref-
erence gene normalisation [31].
Statistical analysis was performed using SPSS 14.0
(Chicago, IL, USA) and Minitab® 15 softwares (Minitab
Ltd, Coventry, UK). Distribution of continuous data was
determined using the Kolmogorov-Smirnov Z test. Two-
sample t test was used to compare log 10 Cq values of
candidate reference genes, and log 10 relative quantities
of target miRNAs between tumour and normal tissues.
The equivalence test was used to determine if reference
genes were equivalently expressed between tumour and
normal tissues [23]. Difference in variance between genes
was assessed using Bartlett's test. P values of less than
0.05 were considered statistically significant for all tests.
Results
Identification of candidate reference genes by using the 
global mean expression value
We profiled a panel of 380 miRNAs and controls in 10
pairs of stage II colorectal tumour and normal tissues. To
identify the most stably expressed miRNAs, a robust
global mean expression normalisation strategy was
applied [25]. For each individual sample, the mean Cq
values of all miRNAs that were expressed, and those that
were expressed below cycle 35 were calculated. Expres-
sion stability of the mean global values, the geometric
means of snoRNAs (U6, RNU44 and RNU48) and miR-
NAs (let-7a, miR-16, miR-17 and miR-103) were assessed
using the GeNorm algorithm. Both the geometric mean
of let-7a and the mean global expression values for all
miRNAs were found to be the most stably expressed. U6
Table 1: Clinicopathological data for 40 patients with 
colorectal cancer (tissues: colorectal tumour n = 35 and 
normal n = 39)
Characteristics (n = 40) Number (percentage)
Age (mean ± standard deviation) 66.7 ± 13.1
Sex
Male 28 (70.0)
Female 12 (30.0)
Location of tumors
Colon 11 (27.5)
Rectum 29 (72.5)
Pathologic T classification
Tx 2 (5.0)
Tis 1 (2.5)
T1 4 (10.0)
T2 9 (22.5)
T3 12 (30.0)
T4 11 (27.5)
N/A 1 (2.5)
Pathologic N classification
Nx 2 (5.0)
N0 22 (55.0)
N1 11 (27.5)
N2 4 (10.0)
N/A 1 (2.5)
Metastasis classification
M0 34 (87.5)
M1 6 (12.5)
AJCC classification
Stage 0 1 (2.5)
Stage I 10 (25.0)
Stage II 10 (25.0)
Stage III 11 (27.5)
Stage IV 6 (12.5)
pCR 2 (10.0)
Differentiation
Well 1 (2.5)
Moderate 24 (60.0)
Poor 8 (20.0)
N/A 7 (35.0)
AJCC, American Joint Committee on Cancer; pCR, pathologic 
complete response following neoadjuvant therapy.
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RNA was the least stably expressed reference gene. Four
miRNAs that showed an expression profile closest to the
mean were miR-26a, miR-345, miR-425 and miR-454.
Two snoRNA genes (RNU48 and Z30) and one other
miRNA (miR-16) [17] were chosen for further validation
in a larger cohort. Known functions of the candidates are
listed in Table 2.
Reference gene quantitation by RT-qPCR
RT-qPCR was performed to further evaluate the expres-
sion patterns of eight candidate reference genes in a
cohort of 74 colorectal tissues. The reference genes dis-
played a wide range of Cq values ranging from 21.09 to
38.90. MiR-16 and miR-26a showed relatively high
expression with mean Cqs of 23.61. Candidates that were
moderately abundant with mean Cqs between 26 and 28
were let-7a, miR-345, miR-425 and RNU48. Z30 and miR-
454 were the least expressed with mean Cqs of above 30.
Among the reference genes, miR-16 showed the least
variability while Z30 displayed the most. Mean and range
of Cq values for all reference genes and target miRNAs
are shown in Table 3.
Using the Cq values of each reference gene, there was
no evidence for differential expression of all of the candi-
date reference genes between tumour and normal tissues
(p > 0.05; Figure 1a), thus supporting further evaluation
of these candidate reference genes. A significant differ-
ence in variance between reference genes (p < 0.001; Fig-
ure 1b) indicated differing stabilities of these candidates.
The equivalence test confirmed that all reference genes
were equivalently expressed between tumour and normal
colorectal tissues (Figure 2). Logarithmised relative
expression values of candidate reference genes were cal-
culated and expressed as means and matching symmetri-
cal confidence intervals. Confidence intervals of between
-1 and 1 correspond with fold change of ≤ 2, whereas con-
fidence intervals of between -1.58 and 1.58 correspond
with fold change of ≤ 3. A fold change cut-off of 3 was
used as previously demonstrated [23]. The upper border
of the confidence interval of > 1.58 indicates higher
expression of a gene in tumours; whereas the lower bor-
der of the confidence interval of < -1.58 indicates higher
expression of a gene in normal tissues.
Analysis of reference genes' expression stability
Variable stability of reference genes was further assessed
using two algorithms: NormFinder [32] and geNorm [22].
The ranking of genes as determined by these programs is
summarised in Table 4. Lower stability values character-
ise greater gene stability. GeNorm generates a gene stabil-
ity value (M) based on the average pairwise variation
between all tested genes accompanied by stepwise exclu-
sion of the least stable gene (Figure 3a). It also generates
V values (V) which define the pairwise variation between
Table 2: Details of candidate reference genes and their amplification efficiencies
Name Length (nt) RNA species Accession number Function E (%)
let-7a 22 miRNA MI0000060* Negatively regulates RAS oncogene [37] 100.0
miR-16 22 miRNA MI0000070* Negatively regulates B-cell lymphoma mRNA in chronic 
lymphocytic leukaemia [38]
100.0
miR-26a 22 miRNA MI0000083* Involved in myogenesis and osteogenic differentiation 
[39,40]
99.8
miR-345 22 miRNA MI0000825* Overexpressed in malignant mesothelioma [41] 100.8
miR-425 22 miRNA MI0001448* No functionally verified targets 101.2
miR-454 22 miRNA MI0003820* No functionally verified targets 101.8
RNU48 63 snoRNA NR_002745** Guides the 2'O-ribose methylation of 28S rRNA [42] 100.0
Z30 97 snoRNA AJ007733** Guides the methylation of the Am47 residue in U6 snoRNA 
[43]
99.4
*mirBase database accession number **Entrez gene ID
rRNA, ribosomal RNA; snoRNA, small nucleolar RNA; E, amplification efficiency.
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two sequential normalisation factors to determine the
optimal number of reference genes for normalisation
(Figure 3b). NormFinder and geNorm identified miR-345
and miR-16 respectively as the most stably expressed ref-
erence genes. Consistent with the results from the Taq-
Man array card using the mean expression values, let-7a,
miR-26a, miR-345, miR-425 and miR-454 were identified
as five of the six most stably expressed genes in the vali-
dation dataset. Both programs selected miR-16 and miR-
345 as the most stable pair of reference genes. GeNorm
recommended the use of five of the six most stable genes
for optimal normalisation, in line with previous reports
that indicate intrinsic higher variability in cancer biop-
sies. Interestingly, miRNAs identified to be the most sta-
bly expressed in stage II tumour and normal tissues using
high-throughput methodology remained consistently sta-
bly expressed in a larger tissue cohort consisting of tis-
sues of varying stages.
Effect of reference genes on relative expression of target 
miRNAs
Of the four target miRNAs evaluated after normalisation
to different references, the choice of reference gene did
not influence the relative quantity of miR-31 (p < 0.001)
between tumour and normal tissues suggesting a highly
significant differential expression of miR-31 in CRC (Fig-
ure 4b). Relative quantities of target miRNAs in tumour
and normal tissues using different normalisers are shown
in Figure 4 and Figure 5 with p values indicated in the
box. When a single gene was used as a reference gene,
only miR-345 and miR-454 detected significant difference
between tumour and normal tissues in all four miRNAs.
The combination of miR-16 and miR-345 detected signif-
icant up-regulation of miR-21 (p = 0.001), miR-31 (p <
0.001), and down-regulation of miR-143 (p = 0.034) and
miR-145 (p = 0.014). These results highlight the impor-
tance of selecting appropriate and validated reference
Table 3: Quantification cycle (Cq) values of candidate reference genes and target miRNAs (in triplicate) in colorectal 
tissues
Reference gene Cq Range Cq Min Cq Max Mean Cq ± s.d.
let-7a 8.02 24.25 32.27 28.31 ± 1.60
miR-16 4.75 21.85 26.60 23.61 ± 1.00
miR-26a 6.96 21.09 28.05 23.61 ± 1.49
miR-345 9.37 25.14 34.51 27.43 ± 1.35
miR-425 10.01 24.65 34.66 27.53 ± 1.36
miR-454 9.64 27.76 37.40 30.14 ± 1.75
RNU48 9.71 22.08 31.79 26.34 ± 2.09
Z30 12.58 26.32 38.90 31.17 ± 2.83
Target miRNA
miR-21 14.21 19.57 33.78 24.82 ± 4.07
miR-31 18.12 20.81 38.93 29.36 ± 3.75
miR-143 12.19 15.95 28.14 23.01 ± 2.84
miR-145 14.03 18.06 32.09 24.84 ± 2.79
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Figure 1 Relative quantity and variation associated with each candidate reference gene. (a) Quantity of candidate reference miRNAs in colorec-
tal tumour (n = 35) and normal (n = 39) tissues as expressed as quantification cycle (Cq) values. Boxplots depict median lines, interquartile-range boxes 
and outliers (*). Error bars represent range of values. No significant difference (p > 0.05, t-test) was found within all reference genes between tumour 
and normal tissues, thus supporting further evaluation of these genes as references. (b) Variation associated with each candidate reference gene. 
There was a significant difference in variance (p < 0.001, Bartlett's test) associated with each reference gene indicating differing stabilities. RNU48 and 
Z30 showed greater variance than miR-16, miR-345 and miR-425.
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genes. Despite the large sample size, true biological dif-
ferences in gene expression were not detected when using
less stable reference genes for normalisation.
Discussion
The discovery of miRNAs as crucial regulators of gene
expression has resulted in the rapid expansion of under-
standing of gene regulation in normal development and
disease. Previously, it was demonstrated that miRNA
expression profiles may be more accurate in disease clas-
sification than mRNA expression profiles [8]. However,
accurate and reliable interpretation of RT-qPCR results
depends heavily on the use of suitable reference genes for
normalisation to eliminate or minimise non-biological
variation between test samples. While reference genes for
mRNA RT-qPCR studies have been well-established, few
miRNA RT-qPCR studies have detailed the validation of
reference genes for normalisation to date. Rigorous nor-
malisation of miRNA data may be more critical than that
of other RNA functional classes [18]. Indeed, their capa-
bility to regulate multiple gene targets within the same
pathway may amplify their biological effects [33], hence
small changes in miRNA expression may be biologically
and clinically significant.
Davoren et al. reported the first systematic assessments
of candidate reference genes for miRNA RT-qPCR analy-
sis in breast cancer [17]. To our knowledge, such assess-
ment and validation of reference genes for CRC studies
has not been reported. The two most commonly used
normalisers U6 and 5S RNAs were shown to be the two
least stable RNA species [18]. The use of rRNAs as refer-
ence genes has been debated as they can be expressed at
Figure 2 Equivalence test for candidate reference genes. Each line indicates the difference in logarithmic (base 2) expression level between tu-
mour and normal tissues, with the upper and lower bars representing the upper and lower limits of symmetrical confidence intervals respectively. All 
genes were equivalently expressed with confidence intervals within fold change of 2 (deviation area 1, -1).
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much greater levels than target RNAs resulting in diffi-
culty quantitating a lowly expressed target RNA [20,22].
Furthermore, rRNAs have been shown to be involved in
apoptosis [34] and cancer [35]. Lastly, it has been argued
before that it's best to normalise genes with reference
genes belonging to the same RNA class [22]. Let-7a was
used as a normaliser in CRC miRNA RT-qPCR studies
[7,10]. However, its tumour-suppressor role in CRC has
been reported [27]. In a previous study, miR-191 and
miR-25 were identified as the most stable pair of norma-
lisers across 13 distinct human tissue types including 5
pairs of colon tumour and adjacent normal tissues. How-
ever, when analysis was performed on an extended cohort
of lung cancer and normal tissues, miR-17-5p and miR-24
were the best normalisers [18]. This demonstrates the
importance of validating suitable reference genes in a tis-
sue-specific context. Suitable reference genes for colorec-
tal tissue-specific studies needs to be further assessed as
previous reports have demonstrated that a single univer-
sal reference gene for all tissue types is unlikely to exist
[19-23].
This is the first report detailing identification and vali-
dation of suitable reference genes for normalisation of
miRNA RT-qPCR in human colorectal tissues. We pro-
filed the expression of 380 miRNAs (including U6 rRNA)
on 20 colorectal tissues. A robust method using the mean
expression value was used to identify the most stably
expressed miRNAs: let-7a, miR-26a, miR-345, miR-425
and miR-454. Mean normalisation was previously shown
to outperform other methods of normalisation in terms
of better reduction of technical variation and more accu-
rate appreciation of biological changes [25]. Validation by
RT-qPCR was subsequently carried out in a larger cohort
of 74 tissues with assessment of three more candidate ref-
erence genes (miR-16, RNU48 and Z30) [17]. Our initial
validation step confirmed no difference in reference gene
quantities between tumour and normal tissues, allowing
subsequent use of NormFinder and geNorm as these
models assume that reference genes are not differentially
expressed between experimental groups. Equivalent
expression of reference genes between tumour and nor-
mal tissues was then confirmed using a fold change cut-
off of 3 [23]. Both NormFinder and geNorm identified
miR-16 and miR-345 as the most stable normalisers. The
five most stably expressed miRNAs in the TaqMan array
card dataset of stage II tumours remained stably
expressed when a larger cohort of variable disease stages
was evaluated. This suggests that true reference genes are
non-functional in the disease process, and should remain
stably expressed throughout all stages, grades and sub-
types.
Table 4: Ranking and best combination of candidate reference genes based on expression stability values calculated by 
NormFinder and geNorm programs
Rank NormFinder geNorm
Gene Stability Gene Stability (M)
Best combination miR-16/miR-345 0.003 miR-16/miR-345 0.994
1 miR-345 0.004 miR-16 1.647
2 miR-16, miR-425 0.005 miR-26a 1.693
3 miR-454 0.006 miR-345 1.697
4 miR-26a 0.007 miR-425 1.780
5 let-7a 0.008 miR-454 1.845
6 RNU48 0.012 let-7a 1.917
7 Z30 0.016 RNU48 2.365
8 Z30 3.212
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Figure 3 GeNorm analysis of candidate reference genes. (a) Ranking of candidate reference genes according to average expression stability. The 
least stable genes with the highest stability measure, M were excluded in a stepwise manner until the two most stable genes remained: miR-16 and 
miR-345. (b) Determination of optimal number of reference genes for normalisation. The GeNorm programme calculates a normalisation factor (NF) 
which is used to determine the optimal number of reference genes required for accurate normalisation. This factor is calculated using the variable V 
as the pairwise variation (Vn/Vn + 1) between two sequential NFs (NFn and NFn + 1). The number of reference genes is deemed optimal when the V 
value achieves the lowest, at which point it is unnecessary to include additional genes in the normalisation strategy. In this instance, the GeNorm out-
put file indicated that optimal normalisation of gene expression could be achieved using the top five most stable reference genes.
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Figure 4 Effect of reference gene choice on relative expression of oncogenic target miRNAs in colorectal tumour (n = 35) and normal (n = 
39) tissues. Boxplots depict median lines, interquartile-range boxes and outliers (*). Error bar represent range of values. Relative expression of onco-
genic miRNAs: (a) miR-21 and (b) miR-31 between colorectal tumour and normal tissues normalised to different reference genes with p values indicat-
ed. The use of the two most stable reference genes: miR-16 and miR-345 detected significant dysregulation both target miRNAs between colorectal 
tumour and normal tissues. Dysregulation of miR-31 was observed regardless of the choice of reference indicating that it's highly differentially ex-
pressed in colorectal cancer.
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Figure 5 Effect of reference gene choice on relative expression of tumour-suppressor target miRNAs in colorectal tumour (n = 35) and nor-
mal (n = 39) tissues. Boxplots depict median lines, interquartile-range boxes and outliers (*). Error bar represent range of values. Relative expression 
of tumour-suppressor miRNAs: (a) miR-143 and (b) miR-145 between colorectal tumour and normal tissues normalised to different reference genes 
with p values indicated. The use of the two most stable reference genes: miR-16 and miR-345 detected significant dysregulation of both miRNAs be-
tween colorectal tumour and normal tissues.
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As evident from our results, inappropriate use of refer-
ence genes can significantly alter the results of target
miRNAs quantitation. With the use of the best combina-
tion of reference genes (miR-16 and miR-345), significant
dysregulation of all four target miRNAs (miR-21, miR-31,
miR-143 and miR-145) was detected. These target miR-
NAs have repeatedly been shown to be dysregulated in
CRC in previous studies. However, despite a relatively
large sample size, when inappropriate reference genes
were used for normalisation, a true biological difference
in expression between tumour and normal was not
detected. Even though miR-345 and miR-454 detected
significant difference between tumour and normal tissues
when used alone as a reference gene, geNorm analysis
identified them as only the third and the fifth most stably
expressed genes. The p values of the differential expres-
sion of the four target miRNAs between tumour and nor-
mal tissues were slightly lower when using the miR-16/
miR-345 combination in most instances, which could
prove significant in a small scale study. Furthermore, pre-
vious studies have reported that the use of more than one
reference genes increases the accuracy of quantitation
compared to the use of a single reference gene [22,32].
Conclusions
The results of our study have important implications for
CRC translational research. The clinical and pathologi-
cally diverse nature of the tissues used in this study
should be of interest to a broad spectrum of the CRC
research community. While it may not be feasible due to
cost and sample availability, the stability of the top six
most stably expressed miRNAs in colorectal tissues (let-
7a, miR-16, miR-26a, miR-345, miR-425 and miR454)
should be assessed to determine the most appropriate
normalisers within each study as patient and tumour
characteristics may vary between different study cohorts.
Furthermore, with evidence to suggest that miRNA
expression in formalin-fixed paraffin-embedded (FFPE)
tissue samples remains relatively stable and consistent
with that in fresh-frozen samples [36], and that reference
miRNA stabilities are extremely consistent between the
two tissue sources procured and processed independently
of one another [18], the reference genes identified in this
study may be useful for miRNA RT-qPCR study in FFPE
colorectal tissues. This study also demonstrated that the
use of the mean expression value is a useful means of
identifying stable reference genes in high-throughput
miRNA profiling studies, and the findings were con-
firmed to be robust after external validation.
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